David Carpenter

Jun 26, 2024 | mondaq.com | Tim Baines |David Carpenter |Keisuke Iwata

Japan is considering whether to require all of its primary listed companies to publish an annual sustainability report which substantively conforms with the standards issued by the IFRS' International Sustainability Standards Board ("ISSB"). The new mandatory disclosure rule would be applied in phases based on the size of market capitalization, with the biggest companies planned to be entering into the scheme from the financial year ending March 2027.

Jun 10, 2024 | mondaq.com | Tim Baines |David Carpenter |Oliver Williams

On May 28 2024, the Biden administration released the "Voluntary Carbon Markets Joint Policy Statement and Principles". This is one of a number of recent international initiatives to "shore up" the voluntary carbon markets (VCM). The Joint Statement makes a number of important and supportive points in favor of the VCM, noting that: High-integrity VCMs, as well as carbon credit markets more broadly, have the potential to support decarbonization efforts within the United States and globally.

Jun 4, 2024 | connectionmodel.com | David Carpenter

Otter.ai: Transforming Client Communication and Time Tracking in Digital MarketingLiving in the ever-evolving digital world, marketers and clients are always on the lookout for innovative solutions that can make their work more efficient. While there are many applications that promote effective client communication and seamless time tracking, there’s no software that works as well as Otter.ai. What Is Otter.ai? Otter.ai is the ultimate meeting manager and transcription tool.

May 27, 2024 | forbes.com | David Carpenter

Get a front row seat to a free online event with the leading experts in psychedelic therapy sharing thoughts on everything from navigating the complexities of psychedelic-assisted training to discussions on epigenetics and how psychedelic experiences can induce lasting changes in DNA expression. The Psychedelic-Assisted Therapy Global Summit returns for a second year with an impressive lineup of speakers sharing insights and innovations in the field.

May 10, 2024 | forbes.com | David Carpenter

The U.S. Food and Drug Administration (FDA) recently announced an upcoming committee meeting intended to discuss an application submitted by Lykos Therapeutics for MDMA-assisted therapy to treat PTSD. The public advisory meeting headed up by the FDA’s Psychopharmacologic Drugs Advisory Committee is scheduled for June 4. It is another significant move forward for MDMA-assisted therapy being made available to patients suffering from PTSD.